Skip to Content

Methamphetamine Pregnancy and Breastfeeding Warnings

Methamphetamine is also known as: Desoxyn, Desoxyn Gradumet

Methamphetamine Pregnancy Warnings

Animal studies have revealed teratogenic and embryocidal effects when high multiples of the human dose were administered. Data on long-term potential for fertility impairment is not available. There are no controlled data in human pregnancy. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use is not recommended unless the benefit outweighs the risk. US FDA pregnancy category: C Comments: Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight; these infants may experience withdrawal symptoms as demonstrated by dysphoria, including agitation and significant lassitude.

See references

Methamphetamine Breastfeeding Warnings

Breastfeeding is not recommending during treatment. Excreted into human milk: Yes Comments: -Breastfeeding should be withheld for 24 to 48 hours if a patient uses methamphetamine while nursing. -The effect of amphetamine in milk on the neurological development of the breastfed infant has not been well studied. -Large dosages of amphetamine might interfere with milk production, especially in women whose lactation is not well established.

-The urinary excretion of amphetamine in a breastfed infant whose mother was taking racemic amphetamine 5 mg four times daily ranged from 0.1% to 0.3% of the mother's urinary excretion; this infant showed no signs of abnormal development during the first 2 years of life. -The urinary excretion in a breastfed infant whose mother took amphetamine 35 mg daily and exclusively breastfed for 6 months ranged from 1.9% to 2.1% of the mother's urinary excretion; this infant experienced no adverse reactions and grew normally and the mother experienced no adverse effect on milk production. -In a study of 20 postpartum women, dextroamphetamine reduced serum prolactin by 25% to 32% (7.5 mg IV dose) and 30% to 37% (15 mg IV dose). Another study showed a 20 mg oral dose of dextroamphetamine produced a sustained suppression of serum prolactin by 40%.

See references

References for pregnancy information

  1. "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.

References for breastfeeding information

  1. "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.